Interní Med. 2009; 11(3): 115-119

Advances in treatment of advanced colorectal carcinoma

MUDr. Igor Kiss Ph.D
Klinika komplexní onkologické péče MOÚ a LF MU Brno

Colorectal carcinoma is among the most common tumours of the gastrointestinal tract. A major advance in the treatment of advanced disease has been the introduction of targeted therapy in the clinical practice. The combination of chemotherapy and biological therapy has exhibited an additive effect reflected in an increase in therapeutic response, a prolonged median survival, and increased secondary operability of an initially inoperable condition, while favourably affecting the quality of life of patients under treatment.

Keywords: targeted therapy, chemotherapy for colorectal carcinoma, bevacizumab, cetuximab, panitumumab, secondary operability.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kiss I. Advances in treatment of advanced colorectal carcinoma. Interní Med. 2009;11(3):115-119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al Český národní webový portál epidemiologie nádorů [online], Masarykova univerzita, [2005], [cit. 2008-2-02], dostupný z WWW: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802 - 8861.
    2. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 2000; 18: 2938-2947. Go to original source... Go to PubMed...
    3. Rothenberg M, Oza A, Bigelow R, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol, 2003; 21: 2059-2069. Go to original source... Go to PubMed...
    4. Saltz L, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 2000; 343: 905-914. Go to original source... Go to PubMed...
    5. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-flourouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised phase III trials. Br J Cancer, 2004; 90: 1190-1197. Go to original source... Go to PubMed...
    6. Twelwes C. The Xeloda Colorectal Cancer Group: capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. European Journal of Cancer, 2002; 38 (suppl. 2) 15-20. Go to original source... Go to PubMed...
    7. Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 2000; 355: 1041-1047. Go to original source... Go to PubMed...
    8. Tournigard C, Andre T, Achille E, el al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. Journal of Clinical Oncology, 2004; 22: 229-237. Go to original source... Go to PubMed...
    9. Tournigand C, Cervantes A, Figer A, at al. OPTIMOX 1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24, 394-400. Go to original source... Go to PubMed...
    10. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX 2, a large randomized phase II study of maintance therapy or chemotherapy free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MCRC). A GERCOR study. J Clin Oncol 2007; 25, abstract 4013. Go to original source... Go to PubMed...
    11. Gruenberger B, Scheithauer W, Tamandl D, et al. Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastase. J Clin Oncol 2007; 25, ASCO, Abstrakt 4060. Go to original source...
    12. Van Cutsem E, Lang I, D´Haens GD, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 (Suppl. abstract 2). Go to original source... Go to PubMed...
    13. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med, 2004; 351: 337-345. Go to original source... Go to PubMed...
    14. Eng C, Maurel J, Scheithauer W, et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25 (June 20 Suppl): 4003. Go to original source...
    15. Sombrero AF, Fehrenbacher L, Rivera F, et al. Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who failed prior oxaliplatin based therapy. The EPIC trial. AACR 2007, abstract LB-2.
    16. Saltz L, Lenz H-J, Hochster H, et al. Randomised phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan refractory colorectal cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 Suppl: 3508. Go to original source...
    17. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008, vol. 26 (18 Suppl. part II.) abstrakt LBA4011. Go to original source...
    18. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomised phase II study. J Clin Oncol 2007;25 Suppl 18S: Abstract 4035. Go to original source...
    19. Humblet Y, Peeters M, Geldetblom H, et al. Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study. Eur J Cancer 2007, Suppl 5 (4): Abstract 3017. Go to original source...
    20. Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): preliminary PK and efficacy data of a randomized study. GI Cancer Symposium 2007; Orlando, abstract 237. Go to original source...
    21. Karapetis C, et al. KRAS mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer results from NCIC CTG co.17: a phase III trial of cetuximab versus best supportive care. Annal of Oncology, 2008; 19, (Supl.8), abstrakt No. LBA6.
    22. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol, 2004; (abstr 3510), 22: 247. Go to original source...
    23. Malik I, Hecht J, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol, 2005; 23: 251 (abstr. 3520). Go to original source...
    24. PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study. [online]. [cit.2008-10-27]. Dostupný na Wide Web: http://clinicaltrials.gov/ct2/show/NCT00115765.
    25. Hochster H, Hartl LL, Ramanathan R, et al. Safety and efficacy of oxaliplatin/fluoropirimidine regiment with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Final analysis of the TREE study: Journal of Clinical Oncology, 2006; 24, (Suppl. June 20), abstrakt 3510. Go to original source...
    26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 2004; 350: 2335-2342. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.